Damian Marron
Damian Marron
Chairman of the Board
Close
Damian Marron
Damian Marron
Chairman of the Board

Damian Marron is an experienced non-executive director, corporate advisor and life science executive with a successful track record of value creation through public and venture capital financing, portfolio planning, M&A, licensing agreements as well as R&D collaborations, both as an executive and in advisory roles. He has notably specialized in immuno-oncology, cell therapy and orphan diseases. Mr. Marron is currently Non-Executive Chair of the Board at Imophoron Ltd,a private UK start-up, Non-Executive Director at Bone Therapeutics a clinical stage, regenerative medicine company listed on Euronext and Resolys Bio, a private, late pre-clinical U.S. startup. He is also Head of Biopharma with Treehill Partners, a global pure-play healthcare advisory firm. Mr. Marron has formerly been chair of the board of directors of PepGen Ltd and the CEO at Agalimmune Ltd, TxCell SA, Cytheris SA, and Trophos SA. Mr Marron is a British and Irish citizen, and he resides in France.

Shares 55,588
Share options
RSU 400,435
Diane Mellett
Diane Mellett
Board member
Close
Diane Mellett
Diane Mellett
Board member

Diane Mellett is a consultant to a number of biotech and medical device companies. She has qualified in both US and UK law and advises biotechnology companies in commercial contract and intellectual property matters. She was formerly General Counsel for Cambridge Antibody Technology (CAT) (LSE: NASDAQ) and led the secondary NASDAQ listing of that company as well as serving on the board of directors. During her time at CAT, she led a successful defense of a contractual dispute with Abbott Pharmaceuticals (now Abbvie) covering the company’s major collaboration partnership regarding Humira┬«, the most successful revenue generating antibody therapy in the pharmaceutical industry to date. Ms. Mellett is a UK citizen, and resides in France.

Shares 122,948
Share options
RSU 466,460
Robert Burns
Robert Burns
Board member
Close
Robert Burns
Robert Burns
Board member

Robert Burns is an advisor to companies developing immune based therapies in cancer and autoimmune indications. He has been involved for more than 30 years in building biotechnology companies focused on immuno-oncology. Dr. Burns is currently Chairman of Affibody AB in Sweden, a company developing novel therapies in autoimmune and inflammation indications. Dr. Burns was a member of the board of directors of Oncos Therapeutics OY prior to the Company’s acquisition of Targovax Oy. He was previously chairman of the board of directors of Haemostatix Limited before it was acquired by Ergomed plc. He was also previously CEO at 4-Antibody AG, Affitech A/S (NASDAQ/OMX) and Celldex Therapeutics Inc (NASDAQ), each an immuno-oncology vaccine and antibody discovery company. Prior to Celldex Therapeutics, Dr. Burns was Director of Technology Licensing at the Ludwig Institute for Cancer Research, an international independently financed not-for-profit research group focused on cancer vaccines and antibody based cancer immunotherapies. He holds a PhD in Chemistry and is a UK citizen, residing in Oxford, United Kingdom.

Shares 298,761
Share options
RSU 43,071
Thomas Falck
Thomas Falck
Board member
Close
Thomas Falck
Thomas Falck
Board member

Mr Falck is an experienced CEO, CFO, Board Chair and Non-Executive Director, Venture Capitalist & Growth Investor with demonstrated success in defining and delivering profitable growth while undertaking strategic and organizational change. He has broad experience with Private Equity, Venture Capital, Stock Listed, Family and Government owned entities.

Mr Falck holds an MBA from The Darden School at the University of Virginia and is a graduate of the Norwegian Naval Academy and the Norwegian Defense University College. In addition, Mr Falck has attended Executive Programs at Singularity University and Harvard Business School.

Shares
Share options
RSU 296,493